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Introduction: Osteoporosis is a skeletal disorder characterized by compromised bone strength 
and increased risk of fracture. It is a common disorder in elderly subjects and represents a major 
public health problem, affecting up to 40% postmenopausal women and 15% of men. Among 
the several therapeutical interventions, hormone replacement therapy (HRT) was traditionally 
seen as the gold standard for preventing osteoporotic fractures in postmenopausal women, as 
well as for the management of menopausal symptoms. However HRT, especially if adminis-
tered long-term, may lead to an increased risk of breast and, when unopposed by progestins, 
endometrial cancers. Alternative therapies include bisphosphonates and raloxifene, a selective 
estrogen receptor modulator (SERM). While the former have been associated with suboptimal 
adherence, the latter was considerably less potent than estrogen and its effect in the prevention 
of nonvertebral fractures remain uncertain.
Aims: The purpose of this article is to review the clinical trials of lasofoxifene, a new SERM 
for the treatment of postmenopausal osteoporosis. The medical literature was reviewed for 
appropriate articles containing the terms “lasofoxifene” and SERMs”.
Evidence review: There are three (phase II or phase III) clinical trials that clearly demonstrate 
efficacy and safety of this new SERM in the suppression of bone loss and the prevention of 
vertebral and nonvertebral fractures. Moreover, lasofoxifene treatment also reduced breast 
cancer risk and the occurrence of vaginal atrophy.
Place in therapy: With its increased potency and efficacy on the prevention of nonvertebral 
fractures lasofoxifene may be an alternative and cost-effective therapy for osteoporosis in 
postmenopausal women.
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Core evidence clinical impact summary for lasofoxifene in the treatment of post-
menopausal osteoporosis
Outcome measure Evidence Implications
Patient-oriented evidence
Fracture risk reduction Clear reduced risk of vertebral and 
nonvertebral fractures in women 
with postmenopausal osteoporosis 
compared with placebo
Breast cancer risk 
reduction
Clear reduced breast cancer incidence 
(all breast cancers) in postmenopausal 
women after three and five years of 
treatment compared with placebo
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Scope, aims, and objectives
Lasofoxifene is a new generation selective estrogen receptor 
modulator (SERM) that has completed the phase III 
development program for the prevention and treatment of 
osteoporosis in postmenopausal women. This compound has 
a remarkably improved oral bioavailability with respect to 
other SERMs due to increased resistance to intestinal wall 
glucuronidation. In both preclinical and short-term phase II 
clinical studies lasofoxifene showed a favorable safety pro-
file and demonstrated a proven efficacy in preventing bone 
loss and lowering cholesterol levels. The recent results from 
phase III clinical trials demonstrated the clinical efficacy of 
this drug in the prevention of fractures and the reduction of 
breast cancer risk.
The purpose of this article is to review the clinical evi-
dence for the use of lasofoxifene in women after menopause 
and to discuss how it will fit into the treatment of postmeno-
pausal osteoporosis.
Methods
Relevant articles were identified on the basis of searches 
in PubMed and EMBASE databases using the terms 
“lasofoxifene”, “CP-336156”, and “selective estrogen receptor 
modulators”. The search was updated on September 30, 2008.
One hundred and seventy-eight articles were found, of 
which 11 were written in languages other than English and 
were excluded (Table 1). Within those publications, one 
report from a phase II clinical trial and 67 review articles 
were identified. Of the 67 review articles, three provided 
systematic review of multiple randomized controlled trials and 
were considered. The phase II clinical study was a two-year 
comparative trial of the skeletal effects of lasofoxifene and 
raloxifene in postmenopausal women. Twenty-five further 
abstracts were identified from the annual meetings of the 
Endocrine Society and the American Society of Bone and 
Mineral Research (ASBMR), of which eight were considered 
relevant. These abstracts presented the results from three 
(Continued)
Outcome measure Evidence Implications
improvement of 
gynecological symptoms
Moderate reduction in vulvar–vaginal atrophy, 
without any improvement on hot 
flushes with respect to raloxifene
Uterine safety Moderate No evidence of clinically significant 
increase in the incidence of endome-
trial hyperplasia or uterine cancer. 
increased risk for developing uterine 
polyps and vaginal bleeding
Occurence of venous 
thromboembolism
Substantial Greater than twofold increase in 
the risk of venous thromboembolic 
events and greater than fourfold 
increase in the risk of pulmonary 
embolism compared with placebo
Mortality rate Limited Slight but significant increase in 
prevalence of all-cause deaths at 
five years in lasofoxifene 0.25 mg/day 
(but not 5.0 mg/day) vs placebo
Disease-oriented evidence
Preservation of bone 
quality
Substantial No pathological bone findings were 
identified in bone biopsies after 
treatment
increase in bone density Clear Prevention of postmenopausal bone 
loss, with an increase in BMD at the 
lumbar spine and the hip compared 
with placebo
Suppression of bone 
turnover
Clear reduction of bone turnover markers 
compared with placebo
Economic evidence
Cost-effectiveness No evidence Cost-effectiveness studies have not 
been performed. if a similar cost will 
be established, lasofoxifene treatment 
could have improved cost-effectiveness 
compared with raloxifene.Core Evidence 2009:4 115
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large, phase III, randomized, double blind, placebo-controlled 
clinical trials with bone mineral density (BMD) or fractures as 
a primary end-point: the Osteoporosis Prevention and Lipid 
Lowering (OPAL) parallel studies, and the Postmenopausal 
Evaluation and Risk-Reduction With Lasofoxifene (PEARL) 
study. Each study provided level 2 evidence on the efficacy 
and safety of lasofoxifene for the treatment of postmenopausal 
osteoporosis. In addition, two clinical documents about 
lasofoxifene were available on the Internet, concerning the 
risk benefit profile of lasofoxifene presented for the 2008 FDA 
application: the “Reproductive Health Drugs Advisory Com-
mittee Briefing Document” and the “Background Document 
for Meeting of Advisory Committee for Reproductive Health 
Drugs”. These documents provided additional and detailed 
evidence on the efficacy and safety of lasofoxifene treatment 
in postmenopausal women. No pharmacoeconomic reports of 
lasofoxifene were identified.
Disease overview
Osteoporosis is a skeletal disorder characterized by com-
promised bone strength and increased risk of fracture.1 It is 
one of the most common disorders in elderly subjects and 
represents a major public health problem, affecting up to 
40% postmenopausal women and 15% of men.2 Worldwide, 
osteoporosis is estimated to be present in over 200 million 
individuals, with 75 million of these in Europe, Japan and 
the US.3 Its clinical significance lies in the occurrence of 
fractures, involving most commonly the forearm, the vertebral 
bodies and the hip, but fractures at other sites may be also 
associated with the disease. Each year in the United States 
more than 1.5 million people suffer hip, vertebral, and wrist 
fractures due to osteoporosis.4 In the European Community, 
in the year 2000, the number of osteoporotic fractures was 
estimated at 3.79 million.3 The occurrence of osteoporotic 
fractures leads to considerable mortality, morbidity, reduced 
mobility and decreased quality of life.5 Moreover, future risk 
of osteoporotic fractures is greatly increased in patients with 
one or more vertebral fractures.6 In 1999, the annual number 
of hip fractures in 15 countries of the EC has been estimated 
to be 500,000, with a total care cost of about 4.8 billion euros 
per year.7 In the US, in 2002 the combined annual costs of 
all osteoporotic fractures have been estimated to be US$20 
billion.8 This burden will further increase in absolute terms 
over the next years because of the aging population.9,8 Given 
the magnitude of the problem, the prevention and treatment 
of osteoporosis is, therefore, of major importance for health 
organizations in all countries.
The major determinant of bone strength and osteoporotic 
fracture risk is BMD, as assessed by dual photon absorpti-
ometry or dual energy X-ray absorptiometry. According to 
World Health Organization (WHO) criteria, osteoporosis is 
defined to exist when BMD values fall more than 2.5 standard 
deviations below the young adult reference mean.1 Many 
studies indicate that the risk of fragility fractures increases 
progressively as BMD declines.10–13 It has been estimated 
that the risk of new vertebral fractures increases by a factor 
of 2.0–2.4 for each standard deviation decrease in BMD, 
irrespective of the site of bone density measurement.10 
However, several other skeletal characteristics contribute 
to bone strength and interact with BMD in determining the 
risk of fracture. These include bone macroarchitecture (shape 
and geometry), bone microarchitecture (at the trabecular and 
cortical level), matrix and mineral composition, as well as 
the rate of bone turnover and the degree of mineralization 
or microdamage accumulation, affecting the structural and 
material properties of bone.14,15 The recognition and mea-
surement of these parameters is becoming more important, 
and their incorporation into algorithms of fracture detection 
remains the subject of active research.
Osteoporosis occurs as the result of multiple mecha-
nisms that together cause loss of bone mass and strength.16 
Failure to acquire optimal bone mass and strength during 
growth and or an unbalance in bone remodeling leading to 
bone loss throughout life may all contribute to the develop-
ment of the disease. In women, osteoporosis and fractures 
mainly occurs as a consequence of estrogen deficiency after 
Table 1 Evidence base included in the review
Category Number of records
Full papers Abstracts
initial search 178 25
  records excluded 174 17
  records included 4 8
Additional studies identified 2 0
Total records included 6 8
Level 1 clinical evidence 
(systematic review, meta analysis)
3 0
Level 2 clinical evidence (rCT) 1 8
Level 3 clinical evidence 2 0
  Trials other than rCT 0 0
  Case reports 0 0
  Expert committee reports 2 0
Economic evidence 0 0
Notes: For definitions of levels of evidence, see Editorial information on the Core 
Evidence website, http://www.dovepress.com/core-evidence-journal
Abbreviation: rCT, randomized controlled trial.Core Evidence 2009:4 116
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menopause and results from an imbalance between bone 
resorption by osteoclasts and bone formation by osteoblasts, 
leading to a net bone loss with each remodeling cycle. 
A decrease in estrogen production from androgen precur-
sors has also been supposed to be a major cause of bone 
loss and osteoporosis in aging men.17,18 The mechanism by 
which estrogen affects bone metabolism is complex and not 
fully elucidated. Possible mechanisms include a decrease 
in osteoclastogenesis, osteoclast apoptosis and additional 
effects on calcium homeostasis.19 Estrogen acts through 
the binding and activation to estrogen receptor (ER). Until 
recently, only one form of ER was known to exist.20,21 With 
the discovery of a new form of the receptor, the ERβ,22,23 
encoded by a different gene, the original form has been now 
identified as ERα. While both the ERs bind estrogen as well 
as other agonists or antagonists (although with different 
affinities), they have distinctly different localizations and 
concentrations in several tissues, including bone.24 In fact, 
concentrations of ERβ are higher in developing cancellous 
bone, whereas concentrations of ERα are higher in develop-
ing cortical bone.25 Moreover, target cells for estrogen action 
may contain varying concentrations of homodimers of one or 
both ERs, as well as ERα and ERβ heterodimers. Structural 
functional differences also exist between ERα and ERβ, 
when complexed with estrogen, allowing for a wide range 
of diverse actions to take place.26–28
In women, the decrease in estrogen production during 
menopause has been associated with other nonskeletal com-
plications involving lipid metabolism, and the cardiovascular 
and nervous systems. Decreasing levels of estrogen have 
been also associated with menopausal vasomotor symptoms, 
such as hot flashes, insomnia, nausea, and vaginal discharge 
or bleeding.
Current therapy options  
and unmet needs
Among the several therapeutical interventions in osteopo-
rosis, hormone replacement therapy (HRT) has tradition-
ally been seen as the gold standard method of preventing 
osteoporotic fractures in postmenopausal women, as well 
as for the management of menopausal symptoms. Other 
potential benefits include the prevention of colon cancer 
and a neuroprotective effect.29 Despite biologically plausible 
mechanisms for cardiac protection by estrogen, and obser-
vational studies indicating that HRT confers cardiovascular 
benefit,30 the Women’s Health Initiative (WHI) and other 
recent randomized controlled trials have failed to confirm 
any potential benefit in reducing the risk of coronary artery 
disease and stroke.31 Indeed, early increases in cardiac event 
and stroke rate have been seen in women taking combina-
tion HRT. Secondary analysis of the WHI trial taking into 
account age categories and years since menopause suggested 
no apparent increase in coronary hearth disease risk for 
women close to menopause (within 10 years of menopause 
and under 60 years of age), but particularly high risks in older 
postmenopausal women.32
Moreover, estrogen replacement, especially if adminis-
tered long-term, may lead to an increased risk of breast and, 
when unopposed by progestins, endometrial cancers.33 Other 
side effects often associated with HRT are fluid retention, 
breast pain, headache, and resumption of menstrual cycle. 
These side effects may be mediated by ERs, acting on a large 
number of downstream signals. Thus, the use of HRT now 
needs to be regarded as a short-term therapy for menopausal 
symptom management with treatment individualized for 
each woman.34 In contrast, estrogen replacement must be 
long-term, possibly lifelong, to have any lasting impact on 
bone health. Alternative therapies for the prevention and 
the treatment of osteoporosis include bisphosphonates, 
calcitonin, vitamin D, selective estrogen receptor modulators 
(SERMs), strontium ranelate and parathyroid hormone.15 
According to their mechanism of action and their prevalent 
effects on osteoblasts and/or osteoclasts (cells involved, 
respectively, in bone formation and bone resorption) all the 
above compounds are generally grouped into two major 
classes (Table 2): antiresorptive (inhibiting bone resorption) 
or anabolic (stimulating bone formation) agents. With this 
classification, antiresorptive treatments include calcium, 
vitamin D and its active analogs, HRT, bisphosphonates, 
SERMS, and calcitonin. The only available compound with 
a clear anabolic effect that stimulates bone formation is para-
thyroid hormone, either in its intact form (hPTH 1–84) or the 
34 aminoacid peptide (hPTH 1–34) now called teriparatide. 
Strontium ranelate is considered a compound with mixed 
antiresorptive and anabolic activity, postulated to increase 
bone formation while reducing bone resorption.
The bisphosphonates (alendronate, risedronate, ibandro-
nate, and zoledronate) are actually the most prescribed medi-
cations for the treatment of osteoporosis. Their benefits are 
restricted to the skeleton where they decrease the risk of ver-
tebral and nonvertebral fractures. Moreover, adverse events 
such as esophagitis or esophageal ulcers, hypocalcaemia, 
osteonecrosis of the jaw and, concerning zoledronate, atrial 
fibrillation have been described in patients on bisphosphonate 
treatment. Even though the incidence of most of these adverse 
events is limited, nonadherence to and poor persistence with Core Evidence 2009:4 117
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bisphosphonates is common.35 Given its additional effects 
on different menopause-related complications, major efforts 
have been made to identify alternatives for HRT in post-
menopausal women. In this respect, SERMs represent a class 
with a growing number of compounds that act as either ER 
agonists or antagonists in a tissue-specific manner.36,37 This 
pharmacological profile may offer the opportunity to dissoci-
ate favorable estrogenic effects on the bone from unfavorable 
stimulatory effects on the breast and endometrium. This class 
of compounds includes chemically diverse molecules that 
lack the steroid structure of estrogens, but possess a tertiary 
structure that allows them to bind to ERα and/or ERβ. Most 
of the unique pharmacology of SERMs as well as their 
agonistic and antagonistic activity on estrogen target tissues 
can be explained by three main interactive mechanisms27 
differential ERα and ERβ expression, differential ER con-
formation on ligand binding, and differential expression and 
binding to the ER of coregulator proteins (coactivators or 
corepressors). Because of their selective estrogen-agonist 
properties on different target tissues, SERMs can be indi-
cated for the prevention or treatment of diseases caused by 
estrogen deficiency, including osteoporosis, without most 
of the undesiderable effects of estrogens. In addition, due to 
their selective estrogen-antagonist properties in the breast, 
SERMs can be also used to prevent or treat breast cancer, in 
which estrogen-agonistic activity is undesiderable.38
Currently there are two main chemical classes of SERMs 
approved for clinical use: the triphenylethylene deriva-
tives tamoxifen and toremifene that are used to treat breast 
cancer, and raloxifene, a benzothiopene derivative indicated 
for the treatment and prevention of osteoporosis and in US 
for the prevention of breast cancer.36,37,39,40,38 All three also 
have beneficial effects on serum lipids, but are associated 
with venous thromboembolism and hot flushes. Moreover, 
although tamoxifen has a positive effect on bone as well, the 
increased risk of endometrial cancer eliminates it as a pos-
sible therapy for postmenopausal osteoporosis. The effects 
of raloxifene on bone are well established. Clinical trials 
demonstrated that at a daily dose of 60 mg is effective in the 
prevention and treatment of postmenopausal osteoporosis and 
vertebral fractures.41–43 This compound also lacks estrogenic 
activity at the uterus but is associated with adverse effects 
such as blood clots and vasomotor symptoms, including hot 
flushes. Both preclinical and clinical reports suggest that 
both tamoxifen and raloxifene are considerably less potent 
than estrogen,44–46 in part due to their reduced bioavailability. 
Moreover, their effect in the prevention of hip and other 
nonvertebral fractures is still uncertain. The benefits of these 
SERMs in reducing the risks of invasive breast cancer and 
vertebral fracture should be weighed against the increased 
risks of venous thromboembolism, fatal stroke, and in case 
of tamoxifen, uterine cancer. A consistent number of women 
taking available SERMs for different indications reported 
moderate or severe vasomotor or gynecologic symptoms 
(especially vaginal dryness and hot flashes) that could hinder 
compliance.34 It is evident that there is a need for a SERM that 
has the desirable tissue-specific estrogenic and antiestrogenic 
actions with minimal side effects.
Newer generation SERMs being investigated for the 
prevention and treatment of osteoporosis in post-menopausal 
women include bazedoxifene, ospemifene, arzoxifene and 
lasofoxifene, which are in phase III clinical trials or undergoing 
regulatory review.40 Other new SERMS have had clinical trials 
suspended prematurely: levormeloxifene, for causing urinary 
incontinence and uterine prolapse, and idoxifene, for resulting 
in increased endometrial thickness on ultrasonography but 
without significant histological abnormality.
Summary of pharmacology 
and preclinical evidence
Mechanism of action, metabolism, 
and pharmacokinetic profile
Lasofoxifene (CP-336156) is potent new generation SERM, 
discovered through a synthetic program aimed at isolating 
novel molecules with good oral bioavailability and higher 
potency in vivo.47–49 It is a naphthalene derivative, third 
generation SERM, structurally distinct from the first- and 
second-generation SERMs raloxifene (a benzothiopene 
derivative), tamoxifen and clomiphene (both triphenyleth-
ylene derivatives) or idoxifene (a pyrrolidine derivative). 
Lasofoxifene exerts significant estrogenic and antiestrogenic 
activity both in vitro and in vivo, targeting any tissues that 
possess ERs, such as bone, uterus, breast, blood vessels, and 
liver. Competitive binding assay experiments demonstrated 
Table 2 Drugs classification for osteoporosis
Antiresorptive drugs Bisphosphonates
Estrogens
Calcitonin
SErMs
Anabolic drugs (Fluorides)
Teriparatide
PTH 1-84
Antiresorptive and anabolic drugs Strontium ranelateCore Evidence 2009:4 118
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high affinity of the compound for both ERα and ERβ. Like 
other SERMs, lasofoxifene specifically binds to human ERα 
even though with high affinity and with a half-inhibitory 
concentration (IC50) which is similar to that seen with estra-
diol and thus at least 10-fold higher than those reported for 
raloxifene, tamoxifen and droloxifene.47,50–52 Lasofoxifene 
also has a high affinity for the human ERβ that is similar to 
estradiol.47
Lasofoxifene is well absorbed orally, very highly bound 
to plasma proteins and almost exclusively metabolized by 
the liver (through both oxidative and conjugative pathways), 
with a long elimination half-life of approximately six days 
(150 hours). This slow elimination is similar to some other 
SERMs, such as tamoxifen (120–168 hours) and toremifene 
(120–144 hours), but is substantially longer than for raloxi-
fene (16–87 hours).53 However, lasofoxifene has a remark-
ably improved oral bioavailability with respect to other 
SERM compounds due to increased resistance to intestinal 
wall glucuronidation. This characteristic is due to its nonpolar 
tetrahydronaphthalene structure, making the compound a 
poorer substrate for glucuronidation.47,54 Conversely, the phe-
nolic groups of benzothiopene derivatives such as raloxifene 
are extensively glucuronidated in the intestinal wall, which 
would account for their poor oral bioavailability and their 
limited in vivo potency.51–53 In a comparative study in the 
rat, lasofoxifene and raloxifene showed bioavailabilities of 
62% and 10%, respectively.47 In humans, both lasofoxifene 
and its metabolites are recovered primarily in the feces and 
secondarily in urine.55 Less than 2% of the administered dose 
of lasofoxifene is recovered unchanged in the urine; hence 
there is little effect in the pharmacokinetics of the drug in 
patients with impaired renal function.
In different studies, lasofoxifene demonstrated linear 
pharmacokinetics over a wide dose range (from  0.01 to 
100  mg).56,57 The mean time until maximum concentration (Tmax) 
is approximately six hours, and the estimated terminal 
elimination half-life (t1/2) is six days. Age, weight, race, mild 
to moderate hepatic or renal impairment or use of concomitant 
medications (ie, ketaconazole, digoxin, or warfarin) have not 
been associated with substantial differences in lasofoxifene 
pharmacokinetics.58–60 Thus, no dosage adjustment of the drug 
should be required for these patient-specific factors.
Preclinical studies with lasofoxifene
The effects of lasofoxifene have been tested in different 
in vitro cell systems as well as in different animal models.51–53 
Lasofoxifene action in both skeletal and extraskeletal tissues 
was evaluated.
In bone cells, lasofoxifene exhibited an estrogen-like 
activity and, similar to estradiol, induced apoptosis of 
osteoclast precursors, thus decreasing bone resorption.61 
Different short-term and long-term in vivo studies in ovari-
ectomyzed (OVX) rats confirmed the in vitro evidence and 
demonstrated that lasofoxifene treatment (at doses of 10 to 
1000 µg/kg/day) reduces bone turnover and is effective in 
protecting from OVX-induced bone loss without any major 
adverse finding.47,61–63 Bone histomorphometry studies of 
the lumbar vertebrae confirmed that the bone-protective 
effects of lasofoxifene were identical to those observed with 
estradiol, indicating that this compound is a full estrogen 
agonist on bone.61,63 In fact, at doses of 10–1,000 µg/kg/day 
lasofoxifene completely blocked the ovariectomy-induced 
decrease in trabecular number and thickness as well as the 
increase in bone resorption indices (osteoclast number, per-
cent osteoclast perimeter, percent eroded perimeter) and bone 
formation indices (labeling perimeter, BFR/BV).61 Long-term 
studies in the same models showed that lasofoxifene main-
tains its efficacy on bone over time without any major adverse 
finding.63 Moreover, peripheral quantitative computerized 
tomography analysis of proximal tibial metaphysis and bio-
mechanical testing of the fourth lumbar vertebra clearly indi-
cated that lasofoxifene treatment maintained bone quality and 
preserved bone strength in treated animals.63 Interestingly, 
lasofoxifene was also effective in the prevention of bone loss 
induced by aging or orchidectomy (ORX) in male models of 
osteoporosis, without significant effects on the prostate,64,65 
suggesting a potential application of this compound for the 
treatment of osteoporosis not only in postmenopausal women 
but also in elderly men. A higher dose (10 to 100 vs 0.01 to 
0.1 µg/kg/day) was required to prevent ORX-induced than 
age-related decrease in bone mass.
Preclinical studies demonstrated additional extraskeletal 
benefits of lasofoxifene on serum lipids47,61–66 as well as chemo-
preventive and therapeutic effects on breast cancer, comparable 
with those of tamoxifen.67,68 No uterine hypertrophic effects 
were observed at doses of 1 to 1000 µg/kg/day in OVX 
rats,47,63 and at doses of 0.1 to 100 µg/kg/day in immature 
(3-week-old) or aged (17-month-old) intact female rats.61
No toxicity was reported in the preclinical literature in 
either female and male rats of different ages.51–53 Importantly, 
at doses that efficiently prevent bone loss, lasofoxifene did 
not significantly affect the uterus or the prostate. Moreover, 
the compound did not appear to have any adverse effects on 
fertility in male rats.69 In female rats, lasofoxifene at different 
doses (0.01, 0.03, and 1 mg/kg/day) significantly affected 
the oestrous cycle after 7–9 days of treatment. Restoration of Core Evidence 2009:4 119
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normal estrous cycle was achieved one to two weeks after the 
suspension of therapy.70 As part of an International Conference 
on Harmonization guideline on reproductive and developmen-
tal toxicity testing for new pharmaceuticals [http://www.fda.
gov/cder/guidance s5a.pdf], a pre- and post-natal study in preg-
nant and lactating female rats was designed.71 Lasofoxifene at 
oral doses of  0.01, 0.03, and 1 mg/kg decreased maternal body 
weight, increased dose-dependently the length of gestation and 
induced dystocia. Higher doses (10 or 100 mg/kg) induced 
teratologic effects.72 Concentrations in maternal plasma were 
similar to those in milk, and increased with increasing dose, 
remaining consistent over a 10 day period.71 Inhibition of 
growth of the F1 offspring after perinatal exposure to lasofoxi-
fene was described, without any other significant effect. No 
effects on the F2 generation were observed. These findings 
were similar to those reported for raloxifene.73
Clinical evidence with lasoxoxifene 
in osteoporosis
Clinical efficacy assessment 
in randomized trials
An extensive development clinical program has been con-
ducted with lasofoxifene, including 23 clinical pharmacology 
studies and 17 phase II/III clinical trials. This development 
program included more than 10,000 women and was designed 
to support the use of lasofoxifene for the prevention or treat-
ment of postmenopausal osteoporosis (Table 3) and for the 
treatment of vulva-vaginal atrophy. Despite positive evidence 
about the skeletal efficacy of lasofoxifene have emerged from 
abstract presentations at different meetings, there is only a 
single phase II trial74 actually published in peer reviewed 
journals. Additional information has been derived from New 
Drug Application documents.75,76
Phase I studies demonstrated that lasofoxifene doses at 
0.1 to 0.5 mg after an overnight fast are well tolerated.56,77 
A pharmacodynamic investigation was performed in a 
randomized, placebo controlled, and multiple oral dose 
study in 64 fasted, female volunteers.57 Included subjects 
were confirmed to be menopausal, within 30% of the ideal 
weight and without any treatment with HRT, SERM, calci-
tonin, sodium fluoride, and calcium supplements within the 
previous three months or bisphosphonates within the previ-
ous 12 months. A loading dose of five times the daily dose 
was followed by lasofoxifene at doses of  0.01, 0.003, 0.1, 
0.3, and 1.0 mg/day or placebo, after a fast of at least eight 
hours for 14 days. A tendency toward decreases in luteinizing 
hormone (LH), follicle-stimulating hormone (FSH), and 
low-density lipoprotein cholesterol (LDL-C) at all doses and 
decreases in N-telopeptide of type I collagen (NTx) at the 
higher doses (0.3 and 1.0 mg/day) was reported. This raised 
the hypothesis that the dosage of 0.3 mg/day is close to the 
maximally effective dose for bone markers. In subsequent 
phase II multiple dose studies early stage safety and efficacy 
of lasofoxifene was studied over a 600-fold dose range (from 
0.017 mg/day to 10 mg/day).78,79 At all doses, the compound 
was well tolerated, without undue toxicity. The overall results 
from the dose selection analyses suggested that the lowest 
lasofoxifene dose necessary to achieve a fully efficacious 
response on BMD and LDL-C levels is 0.25 mg/day.79–81 
All lasofoxifene treatment regimens were also associated 
with improvements in vaginal atrophy measures, namely 
maturation index and vaginal pH, compared with placebo. 
In a different phase II study lasofoxifene increased BMD as 
effectively as conjugate estrogen (‘Prempro’, premarin con-
jugated estrogen with medroxyprogesterone acetate).78,82,83
The key evidence with lasofoxifene for the treatment 
of osteoporosis comes from a phase II comparative trial 
with raloxifene and from 2 phase III trials: the Osteo-
porosis Prevention and Lipid Lowering (OPAL) study, 
and the Postmenopausal Evaluation and Risk-Reduction 
With Lasofoxifene (PEARL) study. All these studies 
assessed the disease-oriented outcomes of BMD and bone 
turnover markers, while only PEARL evaluated the key 
patient-oriented outcome of fractures.
The two-year, phase II study compared the skeletal effects 
of lasofoxifene 0.25 mg/day (n = 82, mean age 59.0 yrs, aver-
age years since menopause: 10) and 1.0 mg/day (n = 82, mean 
age 57.7 yrs, average years since menopause: 9) to raloxifene 
(60 mg/day; n = 163, mean age 57.5 yrs, average years since 
menopause: 9) and placebo (n = 83, mean age 57.5 yrs, aver-
age years since menopause: 8) in 410 postmenopausal women 
(average T score -1.0).74,84,85 All women also received daily 
calcium (1000 mg) and vitamin D (250 IU) supplementation. 
The primary efficacy endpoint of the study was the percent 
change from baseline to two years in lumbar spine BMD. 
Secondary endpoints included total hip BMD and total body 
bone mineral content, the change from baseline of lumbar spine 
at month 6 and year 1, biochemical markers of bone turnover, 
LDL-C, and safety profile. At the lumbar spine, both doses 
of lasofoxifene significantly increased BMD compared with 
raloxifene and with placebo treatment (+1.8 and +2.2% for 
0.25 and 1.0 mg lasofoxifene, respectively; -0.1 and -1.7% for 
raloxifene and placebo, respectively; Figure 1a).84 Conversely, 
the two doses of lasofoxifene and raloxifene were equally 
effective at increasing total hip BMD. Consistent with the Core Evidence 2009:4 120
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effects on BMD, biochemical markers of bone turnover 
(urinary N-telopeptide and deoxypyridinoline crosslinks, 
serum bone-specific alkaline phosphatase and osteocalcin) 
significantly decreased after two years of lasofoxifene treat-
ment with respect to placebo. No major differences were 
observed between the 0.25 mg and 1.0 mg lasofoxifene groups. 
Overall, the effects on bone turnover were similar or greater 
than those observed with raloxifene. At two years, both doses 
of lasofoxifene resulted in greater reductions in LDL-C and 
total cholesterol levels when compared with raloxifene and 
placebo.85 Moreover lasofoxifene-treated women showed 
significantly greater decreases in Apo B100 (-11.7% vs -5%) 
and lipoprotein(a) (-37.7% vs -25.6%) and significantly 
greater increase in Apo A1 (+5.5% vs 1.6%) compared with 
raloxifene-treated women. Lasofoxifene was also effective 
in reducing levels of coagulation factors (fibrinogen, plas-
minogen activator inhibitor-1 [PAI-1], and antithrombin III 
activity) compared with placebo (p  0.05). No differences 
in breast pain were observed with lasofoxifene compared to 
placebo or raloxifene.
Pooled preliminary results from the OPAL studies have 
been only presented in abstract form.86,87 These were two iden-
tical phase III, 24-month, prospective, multicenter, random-
ized, double-blind, placebo-controlled, parallel-group trials 
in 1907 healthy postmenopausal women aged 40 to 75 years 
(3 to 20 years postmenopausal). Among the inclusion criteria 
there was a lumbar spine BMD T score between 0 and -2.5. 
Women were excluded if they had diseases associated with 
altered bone metabolism, malignancy within the previous 
five years, ovarian or uterine pathology, spinal deformities 
that would affect lumbar densitometry, hip prosthesis, or a 
history of nontraumatic vertebral or hip fractures. Following 
a six to eight week placebo run-in period, recruited subjects 
were randomized 1:1:1:1 to receive 24 months of double-
blind treatment with lasofoxifene 0.025 mg/day, 0.25 mg/day, 
and 0.5 mg/day or placebo. All patients received calcium or 
vitamin D supplementation. The primary endpoint was the 
two-year change in lumbar spine BMD, which was evalu-
ated using an a priori fixed sequence multiple comparisons 
procedure on data pooled from both studies.
Lasofoxifene treatment significantly increased BMD 
and decreased bone turnover compared to placebo, with 
beneficial changes observed as early as six months.86 
All three lasofoxifene doses were able to significantly 
increase lumbar and femoral BMD at 6, 12, and 24 months 
as compared with a decrease observed in calcium and 
vitamin D supplemented placebo group. At two years, lumbar 
BMD increased by 1.5%, 2.3%, and 2.3% in lasofoxifene 
Table 3 Phase II/III trials of lasofoxifene for osteoporosis prevention or treatment
Study Design Treatment groups Primary endpoint
Phase II
  A2181037 (JADE) Treatment LAS 0.025, 0.25 and 
0.50 mg/day vs PB
1-year change in lumbar spine BMD
  A2181042 (LACE) Prevention LAS 0.25 mg/day vs PB 2-year change in lumbar spine BMD
  218–101 Prevention LAS 0.4, 2.5 and 
10 mg/day vs Conj. 
Est/MPA or PB
3-months change in bone markers
  218–101E Prevention LAS 0.4, 2.5 and 
10 mg/day vs Conj. 
Est/MPA or PB
1-year change in lumbar spine BMD
  218–102 Prevention LAS 0.25 and 
1.0 mg/day vs RAL 
60 mg/day or PB
2-year change in lumbar spine BMD
  218–103 Prevention LAS 0.017, 0.05, 0.15 
and 0.50 mg/day vs PB
1-year change in lumbar spine BMD
Phase III
  A2181003/004 (OPAL) Prevention LAS 0.025, 0.25 and 
0.50 mg/day vs PB
2-year change in lumbar spine BMD
  A2181002 (PEArL) Treatment LAS 0.25 and 
0.50 mg/day vs PB
New/worsening radiographic vertebral 
fracture
  A2181030 (COrAL) Prevention LAS 0.25 mg/day vs RAL 
60 mg/day or PB
Change in lumbar spine BMD and 
percent of BMD response after 2-years
Abbreviations: BMD, bone mineral density; Est, estrogen; LAS, lasofoxifene; MPA, medroxyprogesterone acetate; PB, placebo; rAL, raloxifene.Core Evidence 2009:4 121
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0.025 mg/day, 0.25 mg/day, and 0.5 mg/day treatment 
groups, respectively, as compared with a decrease of 0.7% 
with placebo (Figure 1b). A significant decrease in bone 
turnover markers (osteocalcin, CTX, and P1NP) was also 
observed at six and 24 months in lasofoxifene treatment 
groups with respect to placebo. Moreover, bone biopsies in 
lasofoxifene-treated subjects showed bone of normal quality. 
Changes in signs and self-assessed symptoms of vaginal 
atrophy or cognitive function and variations in lipid levels 
were also periodically analyzed over 24 months.87 Neither 
breast density, assessed by mammography in 351 women, nor 
breast pain increased in the lasofoxifene groups. There was a 
significant improvement in vaginal pH at 12 and 24 months 
for all doses of lasofoxifene versus placebo. The assessment 
of the degree of vaginal maturation indicated significantly 
lower percentages of parabasal cells and significantly higher 
proportions of intermediate and superficial cells at 12 and 
24 months in lasofoxifene-treated women with respect to 
placebo. The evaluation of cognitive function and mood in 
a subset of patients (n = 267) did not show any difference 
between lasofoxifene and placebo groups, except a lower 
CESD-10 depression score at 12 months and a lower Digits 
Forward score in 0.025 mg group; neither results were judged 
to be clinically meaningful. At all time points lasofoxifene 
treatment was associated with significant reductions in 
LDL-C relative to placebo. LDL-C reductions were sig-
nificantly greater in the 0.25 and 0.5 mg/day groups than in 
the 0.025 mg/day group. Similar reductions were observed 
in total cholesterol, high density lipoprotein cholesterol 
(HDL-C), total cholesterol/HDL-C ratio, apolipoprotein 
B100, apolipoprotein B100/apolipoprotein A1 ratio, and 
lipoprotein a, in all treatment groups. Relative to placebo, 
lasofoxifene 0.25 and 0.5 mg/day were associated with 
small but significant increases in tryglicerides from baseline 
at all time points. At 24 months, all lasofoxifene treatment 
groups were associated with significantly greater reductions 
in the prothrombotic marker fibrinogen and high sensitivity 
C-reactive protein compared with placebo.
The PEARL trial was a randomized, double-blind, 
placebo-controlled, parallel assignment study aimed to deter-
mine the safety and effectiveness of two doses of lasofoxifene 
in reducing the risk of new/worsening radiographic spinal 
fractures (primary endpoint) in women with osteoporosis;78 
http://www.clinicaltrials.gov/ct]. Secondary outcomes 
included nonvertebral fractures, BMD, bone markers, breast 
cancer, cardiovascular events, and gynecological safety 
events. Osteoporotic postmenopausal women (n = 8556, BMD 
T score  -2.5 SD, age range 59–80 yrs) were included in 
the study if they had no other metabolic bone disease, if they 
were not taking medications approved for osteoporosis, if they 
have had no recent fracture (within one year), no more than 
three prevalent vertebral fractures on baseline X-ray and/or a 
BMD  -4.5 SD at the lumbar spine or the femoral neck. The 
study was originally designed as a three-year study, but was 
extended by two additional years via a protocol amendment 
in order to provide long-term exposure data.
Results have been recently released in abstract form,88–90 
as well as in two additional documents [http://www.fda.
gov/ohrms/dockets], but have not yet been published in 
peer-reviewed papers.
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At three years, lasofoxifene significantly reduced bone 
turnover markers and improved BMD at the spine (3.3% 
for both doses; p  0.001) and femoral neck (2.7% for 
0.25 mg and 3.3% for 0.5 mg; p  0.001), compared with 
placebo. A significant reduction in vertebral fracture risk was 
demonstrated with both treatment arms (31% for 0.25 mg; 
p = 0.002 and 42% for 0.5 mg; p  0.001) (Figure 2). This 
effect was observed as early as one year for both doses of 
lasofoxifene and was sustained through five years. A similar 
risk reduction was observed with both doses in women with 
or without prevalent fracture at baseline. The risk of non-
vertebral fractures at three years was significantly reduced 
by 22% (p = 0.02) in the lasofoxifene 0.5 mg group and 
was maintained through five years (Figure 3). Consistent 
with the data on vertebral fractures, the significant effect of 
lasofoxifene 0.5 mg on nonvertebral fractures was observed 
as early as one year. Conversely, lasofoxifene 0.25 mg did 
not significantly reduce nonvertebral fracture risk at any 
time point. Of interest, lasofoxifene 0.25 mg and 0.5 mg 
also reduced the risk of ER-positive breast cancer (by 84% 
and 67%, respectively) and of all breast cancers (Figure 4). 
This effect was maintained (79% reduction of all breast 
cancers) after five years with lasofoxifene 0.5 mg. Efficacy 
of lasofoxifene treatment on vulvar and vaginal atrophy 
endpoints (symptoms, vaginal pH and maturation index, 
percentage of parabasal cells and of superficial cells) was 
also demonstrated with both lasofoxifene doses.
Safety and tolerability
In all clinical trials performed to date, lasofoxifene appeared 
to be well tolerated.56,77,78,87 In general, adverse events were 
mild or moderate and usually resolved within a few days, 
without treatment discontinuation. Moreover, there were no 
changes in adverse event frequency or intensity with increas-
ing dose. In a comparative phase II study, the adverse event 
profile of lasofoxifene was similar to that of raloxifene with 
respect to increases in hot flashes and leg cramps compared 
with placebo.84 These appear to be class effects of SERMs.91 
An increased frequency of urogenital symptoms (mainly 
increased vaginal moisture, considered to be beneficial by 
some women) were observed in lasofoxifene-treated groups 
compared with the raloxifene-treated group.84 This is consis-
tent with preclinical observations showing that lasofoxifene 
stimulates vaginal mucus formation without causing cell 
proliferation in the rat reproductive tract.92 Vasodilatation 
was an additional adverse event attributed to lasofoxifene 
treatment in another one-year study on healthy postmeno-
pausal women.80 In phase III studies adverse events reported 
by more than 5% of lasofoxifene treated subjects included hot 
flashes, leg cramps and increased vaginal moisture.87,90
Major general safety events of special interest for any 
SERM have been comprehensively addressed in phase III 
clinical trials, as secondary endpoints. There were two safety 
findings of note associated with lasofoxifene treatment: an 
increased incidence of uterine diagnostic procedures and an 
increase in venous thromboembolic events. Even though 
the larger clinical safety database from the PEARL trial 
does not show evidence of an increased risk of endometrial 
cancer or hyperplasia associated with the use of lasofoxi-
fene for five years, gynecologic adverse events occurred 
more frequently than placebo;90 http://www.clinicaltrials.
gov/ct]. These included uterine polyps and endometrial 
hypertrophy, both considered benign findings, as well as an 
increased reporting of uterine prolapse. The latter was not 
confirmed by comprehensive and specific rating scales used 
to evaluate pelvic organ prolapse, nor was there a significant 
increase in prolapse surgery through five years of follow-up 
in the PEARL trial. Benign effects on the endometrium were 
characterized by an approximate 1.5 mm mean increase in 
endometrial thickness and increased cystic echotexture on 
ultrasound, which are consistent with benign cystic atrophy 
on biopsy. These effects have been attributed to increased 
vascular permeability by lasofoxifene, which results in uter-
ine imbibition and accumulation of fluid in both the glands 
and stroma of the endometrium, consistent with the cystic 
echotexture and increased endometrial thickness observed 
on ultrasound, together with the benign cystic atrophy 
observed on biopsy. In the PEARL study, vaginal bleeding 
was reported with low frequency, but was more common in 
lasofoxifene-treated patients compared to placebo. This small 
increase in vaginal bleeding, together with asymptomatic 
benign endometrial findings detected in unplanned trans-
vaginal ultrasound, contributed to the observed increase in 
diagnostic uterine procedures. During the five years follow 
up of the PEARL study, lasofoxifene was associated with 
an approximate twofold increased risk of venous thrombo-
embolism, mainly driven by an increased risk of deep vein 
thrombosis.90 In fact, pulmonary embolism occurred less 
frequently than deep vein thrombosis (0.2% vs 0.8%, respec-
tively) but was also significantly increased in lasofoxifene-
treated patients compared to placebo (hazard ratio [HR] 4.49, 
95% confidence interval [CI]: 0.97–20.79 for lasofoxifene 
0.5 mg and HR 5.98, 95% CI: 1.33–26.72 for lasofoxifene 
0.25 mg). Conversely, lasofoxifene was not associated with 
an increased risk of stroke. Indeed, while the prospectively-
defined analysis included transient ischemic attacks (TIAs), Core Evidence 2009:4 123
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an analysis excluding TIAs showed lasofoxifene to be 
associated with a decreased risk of stroke.
Consistent with preclinical data, both three- and five-year 
data from the PEARL study clearly showed that lasofoxifene 
treatment is associated with a reduction in risk of breast 
cancer (this was a co-primary endpoint in the PEARL study at 
five years). This effect was evident with lasofoxifene 0.5 mg 
for all breast cancers, ER+, invasive, and ER+ invasive breast 
cancers which was not consistently observed with lasofoxi-
fene 0.25 mg [http://www.clinicaltrials.gov/ct].
Importantly, lasofoxifene 0.5 mg was associated with a 
significant 32% reduction in major coronary events (includ-
ing coronary death, nonfatal myocardial infarctions, coronary 
revascularization procedures, documented new ischemic heart 
disease, and hospitalizations for unstable angina) through five 
years [http://www.clinicaltrials.gov/ct]. Markers of cardio-
vascular risk (total cholesterol, LDL-cholesterol, and high 
sensitivity C-reactive protein) were measured at three years 
and showed a significant reduction in lasofoxifene-treated 
subjects compared to placebo.
Economic evidence
Pharmacoeconomic evaluation on the use of lasofoxifene in 
osteoporosis prevention or treatment has been not released. 
Moreover, although several articles addressed the economic 
value of specific agents, the cost-effectiveness of all currently 
available drugs approved for the treatment of osteoporosis 
has not been reported. Antiresorptive agents are considered 
effective in reducing fracture incidence and generally have 
favorable cost-effectiveness profiles for most postmeno-
pausal women with osteoporosis.93,94 Recent results from the 
US further support the treatment of high risk postmenopausal 
populations because of the gain in quality-adjusted life 
years (QALYs) and, in women aged 75 years with previous 
fracture, overall cost savings because of the reduction in 
health care services.95 The WHO recently developed a clini-
cal tool for calculation of the 10-year probability of fracture, 
that can be used in combination with country specific data 
(ie, fracture rates, health care costs) to develop cost-effective 
intervention thresholds for osteoporosis treatment. Using 
US-specific data, the cost-effectiveness for treatment is 
reached when the 10-year probability of hip fracture using 
the WHO algorithm is approximately 3% or above.96
To date, few studies have considered the favorable 
extraskeletal effects of SERMs or the impact of drug 
side effects on the cost-effectiveness of treatment. In this 
context, it is important to differentiate between the qual-
ity of life impact caused by the antifracture efficacy of an 
intervention and any general quality of life impact that it 
may have independently of that antifracture efficacy. In 
a UK meta-analysis considering postmenopausal women 
unselected for low BMD and modeled for additional con-
ditions such as breast cancer and cardiovascular health, 
only raloxifene proved cost-effective for the prevention of 
vertebral fractures at 60 years of age, with a cost per QALY 
of £26,000 (assuming no impact on hip fractures) that was 
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below the estimated threshold of £35,000 corresponding to no 
treatment (with the assumption that all women had sufficient 
intakes of calcium and vitamin D).97 Bisphosphonates such 
as alendronate, etidronate, and risedronate had a cost per 
QALY above that threshold. Moreover, none of the consid-
ered interventions was shown to cost-effectively reduce the 
risk of nonvertebral fractures in women unselected for low 
BMD. These net costs were markedly different by age, with 
some treatment regimens becoming cost-saving at higher 
age-ranges in patients with a prior fracture.
Long-term phase II studies and the recent results from 
the PEARL phase III trial show that lasofoxifene has an 
improved profile in bone parameters (ie, markers of bone 
resorption and BMD) with significant improvement in frac-
ture prevention (particularly in nonvertebral fractures) over 
the current leading SERM, raloxifene. This new SERM also 
retains a similar positive effect in breast cancer prevention to 
raloxifene, with potentially improved cardiovascular benefits. 
Thus if lasofoxifene will be marketed at a similar cost to 
current products its cost-effectiveness should be improved 
with respect to raloxifene.
Patient group/population
Preliminary evidence from randomized phase III clinical 
trials, released in abstract form, has shown vertebral and 
nonvertebral fracture risk reduction with lasofoxifene 
0.5 mg/day in postmenopausal women with postmeno-
pausal osteoporosis with or without a previous fracture. 
Potential additive beneficial effects of treatment include 
vaginal atrophy, breast cancer prevention and heart disease. 
Confirmation of such positive results in these areas would 
make the drug very attractive to patients at risk for those 
conditions and postmenopausal bone loss, vastly extending 
the drug’s patient potential. Some concerns on the overall 
risk/benefit profile of lasofoxifene are related to the slight 
increase in the number of deaths observed at five years 
in the PEARL study in subjects treated with lasofoxifene 
0.25 mg/day versus placebo (90 vs 65, respectively). 
Moreover, because treatment with lasofoxifene, similar to 
other SERM compounds, is associated with hot flushes, deep 
venous thromboses, pulmonary embolism, and leg cramps, 
patients taking this SERM should be informed of these 
adverse events. Potential increased risk of vaginal bleeding, 
mainly due to uterine polyps, should be also reported in the 
lasofoxifene drug product label.
Dosage, administration, 
and formulations
According to the recent NDA application (22–242), and based 
on the improved clinical efficacy on bone and extraskel-
etal endpoints of lasofoxifene 0.5 mg versus 0.25 mg, 
the compound will be supplied as 0.5 mg, film-coated 
tablets (lasofoxifene tartrate 0.5 mg; Fablyn®, Ligand 
Pharmaceuticals Inc./Pfizer Inc.) for daily oral administration. 
Initial pharmacokinetic studies demonstrated that food does 
not significantly affect the bioavailability of single doses of 
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lasofoxifene relative to the fasting state.77 Therefore the drug 
can be dosed without regard to the timing of meals.
Place in therapy for lasofoxifene 
in osteoporosis
During the past 10 years, several efforts have been devoted 
to the understanding of ER system and the development 
of compounds that interact with intracellular ERs in target 
organs as estrogen agonist and antagonists. The search for a 
SERM molecule with an ideal pharmacologic profile, which 
has estrogen-like activity on the bone and the lipid profile, 
antiestrogenic activity on the breast and neutral activity on 
the uterus, represented for many years the goal to be achieved 
by pharmaceutical companies. This need has been further 
emphasized by the recent negative results from WHI and 
other randomized controlled trials on HRT,31 particularly 
for long-term treatment regimens in late postmenopausal 
women.32 Thus far, a very versatile group of SERMs have 
been developed, with potentially different indications 
and different compounds are actually under investigation. 
However, although currently available SERMs possess many 
benefits, they are also responsible for some very serious 
side effects, such as thromboembolic disorders and uterine 
cancer. These contraindications represent a major concern 
for the type of long-term, chronic therapy that is required 
to prevent osteoporosis. Moreover, a consistent proportion 
of women taking available SERMs for different indications 
reported moderate or severe vasomotor or gynecologic 
symptoms (especially vaginal dryness and hot flashes) that 
could hinder compliance. These side effects have been also 
reported for most of the new SERMs under development, 
including arzoxifene, droloxifene and idoxifene, as well as 
for raloxifene, the only SERM compound actually approved 
worldwide for the prevention and treatment of osteoporosis. 
Moreover, both preclinical and clinical reports suggest that 
these SERMs are considerably less potent than estrogen, 
probably due to their reduced bioavailability.44–46
In this context, lasofoxifene appears to be a promising 
new SERM for the prevention and treatment of osteoporosis. 
Due to increased resistance to intestinal wall glucuronidation, 
this compound has shown a remarkably improved oral 
bioavailability and increased in vitro and in vivo potency 
with respect to other SERMs. Moreover, lasofoxifene shows 
a beneficial pharmacologic profile on bone, breast, and serum 
lipids, without any major adverse effects on the uterus. In 
fact, even though there was an increased percentage of 
patients reporting endometrial polyps and vaginal bleeding 
leading to more gynecologic procedures during lasofoxi-
fene treatment, there is no evidence of increase endometrial 
carcinoma or endometrial hyperplasia in the lasofoxifene 
treated-women compared to placebo. Interestingly, the 
chemopreventive and therapeutic effects of lasofoxifene on 
animal models of breast cancer appear higher than those of 
raloxifene, and comparable with those of tamoxifen. Potential 
additional benefits that lasofoxifene may have over raloxifene 
include its beneficial estrogen-like effects on urogenital 
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atrophy. This latter issue has been recently addressed in 
planned interim analysis from a placebo-controlled trial on 
postmenopausal women78 and might represent an important 
benefit since about 40% of women, potential users of SERMs, 
report vaginal dryness and other complications associated 
with urogenital atrophy (ie, vaginal discharge and infections, 
recurrent urinary tract infections, and dyspareunia).
In 2004, following the positive results of phase II/III 
studies on postmenopausal women, Pfizer decided to submit 
two new drug applications (NDA) to the US Food and 
Drug Administration (FDA) for lasofoxifene 0.25 mg for 
the prevention of osteoporosis in postmenopausal women 
(NDA 21–757) and for the treatment of moderate to severe 
symptoms of vaginal atrophy in postmenopausal women 
with low bone mass (NDA 21–843). In not-approvable 
letters issued in 2005 for osteoporosis prevention and 2006 
for treatment of vaginal atrophy, the FDA acknowledged that 
efficacy had been demonstrated for both indications, but stated 
concerns regarding a hypothetical risk of endometrial cancer 
and an increased risk of invasive gynecological procedures. 
Based on the positive results of the long term (three years), 
phase III, fracture trial PEARL and of the two-year extension 
on safety concerns, a new application (NDA 22–242) has been 
recently submitted to request approval of Fabyln® (lasofoxi-
fene tartrate, 0.5 mg tablets) for the treatment of osteoporosis 
in postmenopausal women at increased risk of fracture.
Due to the reporting out of PEARL at five years, the 
lasofoxifene safety database at the time of this NDA 
submission for the treatment of osteoporosis was about seven 
times larger than that provided in the previously submitted 
NDAs.
The available results from PEARL demonstrate that 
lasofoxifene 0.5 mg significantly reduced the risk of 
new/worsening radiographic vertebral fracture, the risk 
of nonvertebral fracture, and the risk of clinical fracture 
in postmenopausal women with osteoporosis. Significant 
risk reduction for these parameters was seen as early as 
one year and was sustained through five years of treatment. 
Overall, these results on skeletal outcomes are consistent 
with preclinical or preliminary phase II comparative obser-
vations74 and indicate an improved efficacy of lasofoxifene 
over raloxifene. Additionally, lasofoxifene 0.5 mg seemed 
to exert comparable clinical efficacy in reducing the risk of 
breast cancer (ER+, all, ER+ invasive, and invasive) than 
raloxifene, with a risk reduction that was equivalent to that 
observed in the MORE and CORE trials.98,99 Moreover, the 
recent enlargement of the safety database with the inclusion 
of five-year results from the extension of the PEARL trial has 
allowed a more robust assessment of the benefit-risk profile 
of lasofoxifene for the treatment of osteoporosis in postmeno-
pausal women and has enabled Pfizer to address the specific 
concerns on gynecological safety previously raised by the 
FDA. Despite a twofold greater number of women within 
each lasofoxifene group (0.25 and 0.5 mg) that underwent 
one or more uterine procedures than in placebo group, there 
was no evidence of a clinically significant increase in the 
incidence of uterine cancer or endometrial hyperplasia over 
the five years of treatment. An increased number of patients 
with vaginal bleeding, along with increased endometrial 
thickness and increased endometrial polyps, appeared as 
the major causes leading to more gynecologic procedures 
in lasofoxifene treated subjects. Even though of less clinical 
significance than endometrial cancer, these adverse events 
might impact the overall risk–benefit profile of the com-
pound. Other additional concerns of lasofoxifene treatment 
are the increased percentage of subjects with venous throm-
boembolic events (largely due to deep vein thrombosis) and 
a slightly increased percentage of all-cause mortality on both 
the three- and five-year safety data compared with placebo. 
Unexpectedly, the percentage of subjects who died in the 
0.25 mg lasofoxifene group exceeded that in the 0.5 mg 
group and was statistically greater than that in the placebo-
treated subjects based on five-year data. The excess numbers 
of deaths were found primarily in the noncoronary vascular 
and cancer categories. The latter did not appear to be focused 
in any specific organ system. Slightly more cancer deaths 
occurred in the brain, lung, and gastrointestinal system in 
the lasofoxifene-treated subjects. The impact of these find-
ings on the overall risk/benefit profile of lasofoxifene for 
the proposed indication remains unclear and needs further 
investigation.
In addition to the improved efficiency on the prevention of 
vertebral fractures and to the significant effect on the preven-
tion of nonvertebral fractures (that was not demonstrated with 
raloxifene) additional benefits of lasofoxifene over currently 
available SERMs are the beneficial effects on urogenital atro-
phy and the cardiovascular system. Confirmation of such posi-
tive results in these areas would make the drug very attractive 
to patients at-risk for those conditions and postmenopausal 
bone loss, vastly extending the drug’s patient potential. No 
information at all is available addressing the pharmacoeco-
nomic aspects of a treatment with lasofoxifene.
In conclusion, consistent with the encouraging pre-
clinical evidence, the recently presented results from 
PEARL trial indicate that lasofoxifene may represent a 
valid alternative to HRT or raloxifene in the treatment of Core Evidence 2009:4 127
Evidence of therapeutic value of lasofoxifene in osteoporosis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
postmenopausal osteoporosis. Specific studies on different 
outcomes (ie, the prevention of breast cancer or coronary 
events in high-risk populations) and longer term analysis in 
larger samples concerning clinically relevant adverse events 
will be needed to obtain a reasonable view of the future and 
cost-effectiveness of this compound in the management of 
women’s health following menopause.
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